Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2007-03-14
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OSI Pharmaceuticals
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or cytological).

• Received prior chemotherapy treatment for advanced, metastatic non-small cell lung cancer.

• Measurable disease per RECIST criteria.

• Adequate bone marrow, hepatic and renal function.

Exclusion Criteria:

• Breast cancer or skin cancer at any time in the past or any other cancer in the past 5 years.

• Brain metastases that are unstable, require steroids, are life-threatening or required radiation in the last 28 days.

• Known hypersensitivity to minocycline.

• History of serious cardiac disease that is not controlled.

• Serious eye conditions.

• Prior treatment with inhibitors of EGFR of any kind.